Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | APLNR | P35414 | 2/20 | 0.34 |
| ▸ | FDPS | P14324 | 2/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MLNR | O43193 | 1/20 | 0.32 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | FYN | P06241 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.32 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1968777 | 1.00 | KMT2A (0.47) | KMT2AAPLNRFDPSHRH3CYP2D6 | |
| SCHEMBL20762013 | 0.79 | APLNR (0.36) | KMT2AAPLNRFDPSCYP2D6MEN1 | |
| SCHEMBL25040341 | 0.79 | APLNR (0.36) | KMT2AAPLNRFDPSCYP2D6MEN1 | |
| Hydrochloric Acid SCHEMBL20744622 | 0.78 | KMT2A (0.38) | KMT2AAPLNRFDPSCYP2D6MEN1 | |
| SCHEMBL13961615 | 0.75 | CYP2D6 (0.43) | KMT2AFDPSHRH3CYP2D6MEN1 | |
| SCHEMBL353883 | 0.74 | KMT2A (0.54) | KMT2AFDPSHRH3CYP2D6MEN1 | |
| SCHEMBL20744329 | 0.73 | FDPS (0.42) | KMT2AFDPSHRH3CYP2D6MEN1 | |
| SCHEMBL16333481 | 0.73 | KMT2A (0.53) | KMT2AFDPSHRH3CYP2D6MEN1 | |
| Hydrochloric Acid SCHEMBL20744671 | 0.72 | KMT2A (0.44) | KMT2AFDPSHRH3CYP2D6MEN1 | |
| SCHEMBL16538805 | 0.72 | KMT2A (0.41) | KMT2AFDPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10246462-B2 | Chemokine receptor modulators and uses thereof | FLX BIO, INC. (US) | 2019-04-02 | — | — | US | disclosed |
| US-10246462-B2 | Chemokine receptor modulators and uses thereof | FLX BIO, INC. (US) | 2019-04-02 | — | — | US | disclosed |
| US-20180072743-A1 | CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF | RAPT THERAPEUTICS, INC. | 2018-03-15 | — | — | US | disclosed |
| WO-2018049271-A1 | CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF | FLX BIO, INC. (US) | 2018-03-15 | — | — | WO | disclosed |
| US-20180072743-A1 | CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF | RAPT THERAPEUTICS, INC. | 2018-03-15 | — | — | US | disclosed |
| WO-2018049271-A1 | CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF | FLX BIO, INC. (US) | 2018-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10246462-B2 | Chemokine receptor modulators and uses thereof | ACKR3, CCR5, CXCR3 | KMT2A 4753/4885APLNR 176/4885FDPS 2714/4885 |
| US-20180072743-A1 | CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF | ACKR3, CCR5, CXCR3 | KMT2A 4753/4885APLNR 176/4885FDPS 2714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.